English

BioLineRx Ltd.

EDGAR

BLRX Registration statement for a foreign issuer (F-1) · filed 2026-09-25

Annual consolidated revenue for 2025: about USD 1.18M, using the latest reported figures. The previous period, 2024, was about USD 28.94M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

294 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 294000 USD Source

Operating margin

-1,215.31%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -3573000 USD Source
Revenue: 294000 USD Source

Cash and cash equivalents: 4.63 million USD 2026-06-30 Source
Exact value

4627000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-25.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
net income: No compatible figures in this window
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 5 of 11 periods available· newest 2025-12-31
Total liabilities: 5 of 11 periods available· newest 2025-12-31
Current assets: 5 of 11 periods available· newest 2025-12-31
Current liabilities: 5 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-95.9%

Prior period

USD 28.94 million

2024-01-01 – 2024-12-31
Current period

USD 1.18 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1180000 − 28940000 = -27760000 USD

28940000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1180000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · BioLineRx Ltd. · 2025-12-31 BioLineRx Ltd. (edgar:1498403) Year-over-year change in Revenue: -27760000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1180000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#3273230 Filing: 000117891326001581 Input fundies:Revenue: 28940000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#3272229 Filing: 000117891326001581
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 35.8 million

Prior period

−USD 43.87 million

2024-01-01 – 2024-12-31
Current period

−USD 8.07 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-8074000 − -43873000 = 35799000 USD

-43873000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-8074000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · BioLineRx Ltd. · 2025-12-31 BioLineRx Ltd. (edgar:1498403) Year-over-year change in Operating cash flow: 35799000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -8074000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1818282 Filing: 000117891326001581 Input fundies:OperatingCashFlow: -43873000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1817159 Filing: 000117891326001581
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-52.8%

Prior period

USD 53,000

2024-01-01 – 2024-12-31
Current period

USD 25,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

25000 − 53000 = -28000 USD

53000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
25000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · BioLineRx Ltd. · 2025-12-31 BioLineRx Ltd. (edgar:1498403) Year-over-year change in Capital expenditure: -28000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 25000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1831867 Filing: 000117891326001581 Input fundies:CapitalExpenditure: 53000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1830756 Filing: 000117891326001581
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 1.18 million 100% of revenue
Cost of revenue USD 230,000 19% of revenue
Operating expenses USD 11.24 million 952% of revenue
Operating income −USD 10.29 million −872% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −USD 8.07 million −684% of revenue
Capital expenditure USD 25,000 2.1% of revenue
Free cash flow Derived −USD 8.1 million −686% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	0	24777000 Derived	-24777000	Unavailable	Unavailable	-23670000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -24777000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -23573000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 97000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	0	29157000 Derived	-29157000	Unavailable	Unavailable	-26371000 Derived	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -29157000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -26240000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 131000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	4800000	54494000 Derived	-49694000	Unavailable	Unavailable	-22724000 Derived	Source 2023-01-01 – 2023-12-31: 4800000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -49694000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -22608000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 116000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	28940000	49348000 Derived	-20408000	Unavailable	Unavailable	-43926000 Derived	Source 2024-01-01 – 2024-12-31: 28940000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -20408000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -43873000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 53000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	1180000	11467000 Derived	-10287000	Unavailable	Unavailable	-8099000 Derived	Source 2025-01-01 – 2025-12-31: 1180000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -10287000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -8074000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 25000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	0	Revenue: 0 Open source
20222022-12-31	Revenue	0	Revenue: 0 Open source
20232023-12-31	Revenue	4800000	Revenue: 4800000 Open source
20242024-12-31	Revenue	28940000	Revenue: 28940000 Open source
20252025-12-31	Revenue	1180000	Revenue: 1180000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-95.9% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 4800000 Open source Revenue: 0 Open source
20242024-12-31	Year over year	502.9%	Revenue: 28940000 Open source Revenue: 4800000 Open source
20252025-12-31	Year over year	-95.9%	Revenue: 1180000 Open source Revenue: 28940000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -871.8% 2025

Free cash flow margin -686.4% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	Not reported	Operating Income: -24777000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -29157000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	-1,035.3%	Operating Income: -49694000 Open source Revenue: 4800000 Open source
20242024-12-31	Operating margin	-70.5%	Operating Income: -20408000 Open source Revenue: 28940000 Open source
20252025-12-31	Operating margin	-871.8%	Operating Income: -10287000 Open source Revenue: 1180000 Open source
2021-12-31	Net margin	Not reported	Revenue: 0 Open source
2022-12-31	Net margin	Not reported	Revenue: 0 Open source
2023-12-31	Net margin	Not reported	Revenue: 4800000 Open source
2024-12-31	Net margin	Not reported	Revenue: 28940000 Open source
2025-12-31	Net margin	Not reported	Revenue: 1180000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -23573000 Open source Capital Expenditure: 97000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -26240000 Open source Capital Expenditure: 131000 Open source
20232023-12-31	Free cash flow margin	-473.4%	Revenue: 4800000 Open source Operating Cash Flow: -22608000 Open source Capital Expenditure: 116000 Open source
20242024-12-31	Free cash flow margin	-151.8%	Revenue: 28940000 Open source Operating Cash Flow: -43873000 Open source Capital Expenditure: 53000 Open source
20252025-12-31	Free cash flow margin	-686.4%	Revenue: 1180000 Open source Operating Cash Flow: -8074000 Open source Capital Expenditure: 25000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -8.1M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-23573000	Operating Cash Flow: -23573000 Open source
20222022-12-31	Operating cash flow	-26240000	Operating Cash Flow: -26240000 Open source
20232023-12-31	Operating cash flow	-22608000	Operating Cash Flow: -22608000 Open source
20242024-12-31	Operating cash flow	-43873000	Operating Cash Flow: -43873000 Open source
20252025-12-31	Operating cash flow	-8074000	Operating Cash Flow: -8074000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -8.1M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-23670000	Operating Cash Flow: -23573000 Open source Capital Expenditure: 97000 Open source
20222022-12-31	Free cash flow	-26371000	Operating Cash Flow: -26240000 Open source Capital Expenditure: 131000 Open source
20232023-12-31	Free cash flow	-22724000	Operating Cash Flow: -22608000 Open source Capital Expenditure: 116000 Open source
20242024-12-31	Free cash flow	-43926000	Operating Cash Flow: -43873000 Open source Capital Expenditure: 53000 Open source
20252025-12-31	Free cash flow	-8099000	Operating Cash Flow: -8074000 Open source Capital Expenditure: 25000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

42.9% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	16.3%	Total Liabilities: 13304000 Open source Total Assets: 81391000 Open source
20222022-12-31	Liabilities / assets	33.4%	Total Liabilities: 25543000 Open source Total Assets: 76384000 Open source
20232023-12-31	Liabilities / assets	79.3%	Total Liabilities: 50702000 Open source Total Assets: 63925000 Open source
20242024-12-31	Liabilities / assets	65.4%	Total Liabilities: 25445000 Open source Total Assets: 38906000 Open source
20252025-12-31	Liabilities / assets	42.9%	Total Liabilities: 17560000 Open source Total Assets: 40905000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.95× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	5.91×	Current Assets: 57404000 Open source Current Liabilities: 9719000 Open source
20222022-12-31	Current assets / current liabilities	4.87×	Current Assets: 52001000 Open source Current Liabilities: 10679000 Open source
20232023-12-31	Current assets / current liabilities	1.1×	Current Assets: 47183000 Open source Current Liabilities: 42784000 Open source
20242024-12-31	Current assets / current liabilities	1.76×	Current Assets: 27104000 Open source Current Liabilities: 15406000 Open source
20252025-12-31	Current assets / current liabilities	1.95×	Current Assets: 23681000 Open source Current Liabilities: 12123000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	Unavailable Not reported for this period.	−USD 14.51 million Exact value Exact value: -14513000 USD 2016-01-01 – 2016-12-31: -14513000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioLineRx Ltd. · 2016-12-31 BioLineRx Ltd. (edgar:1498403) Operating Cash Flow: -14513000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14513000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891319000965/blrx-20181231.xml#231871 Filing: 000117891319000965 The citation records this snapshot. The page link may show a newer release later.	USD 52,000 Exact value Exact value: 52000 USD 2016-01-01 – 2016-12-31: 52000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioLineRx Ltd. · 2016-12-31 BioLineRx Ltd. (edgar:1498403) Capital Expenditure: 52000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 52000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891319000965/blrx-20181231.xml#257354 Filing: 000117891319000965 The citation records this snapshot. The page link may show a newer release later.	−USD 14.57 million Calculation and evidence -14513000 − 52000 USD Exact free cash flow: -14565000 USD 2016-01-01 – 2016-12-31: -14513000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 52000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioLineRx Ltd. · 2016-12-31 BioLineRx Ltd. (edgar:1498403) Free cash flow: -14565000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14513000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891319000965/blrx-20181231.xml#231871 Filing: 000117891319000965 Input fundies:CapitalExpenditure: 52000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891319000965/blrx-20181231.xml#257354 Filing: 000117891319000965 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	Unavailable Not reported for this period.	−USD 20.55 million Exact value Exact value: -20547000 USD 2017-01-01 – 2017-12-31: -20547000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioLineRx Ltd. · 2017-12-31 BioLineRx Ltd. (edgar:1498403) Operating Cash Flow: -20547000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20547000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/blrx-20191231.xml#274510 Filing: 000117891320000790 The citation records this snapshot. The page link may show a newer release later.	USD 338,000 Exact value Exact value: 338000 USD 2017-01-01 – 2017-12-31: 338000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioLineRx Ltd. · 2017-12-31 BioLineRx Ltd. (edgar:1498403) Capital Expenditure: 338000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 338000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/blrx-20191231.xml#294639 Filing: 000117891320000790 The citation records this snapshot. The page link may show a newer release later.	−USD 20.89 million Calculation and evidence -20547000 − 338000 USD Exact free cash flow: -20885000 USD 2017-01-01 – 2017-12-31: -20547000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 338000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioLineRx Ltd. · 2017-12-31 BioLineRx Ltd. (edgar:1498403) Free cash flow: -20885000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20547000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/blrx-20191231.xml#274510 Filing: 000117891320000790 Input fundies:CapitalExpenditure: 338000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/blrx-20191231.xml#294639 Filing: 000117891320000790 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	Unavailable Not reported for this period.	−USD 24.19 million Exact value Exact value: -24192000 USD 2018-01-01 – 2018-12-31: -24192000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioLineRx Ltd. · 2018-12-31 BioLineRx Ltd. (edgar:1498403) Operating Cash Flow: -24192000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24192000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/blrx-20201231.xml#295388 Filing: 000117891321000741 The citation records this snapshot. The page link may show a newer release later.	USD 173,000 Exact value Exact value: 173000 USD 2018-01-01 – 2018-12-31: 173000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioLineRx Ltd. · 2018-12-31 BioLineRx Ltd. (edgar:1498403) Capital Expenditure: 173000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 173000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/blrx-20201231.xml#310394 Filing: 000117891321000741 The citation records this snapshot. The page link may show a newer release later.	−USD 24.37 million Calculation and evidence -24192000 − 173000 USD Exact free cash flow: -24365000 USD 2018-01-01 – 2018-12-31: -24192000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 173000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioLineRx Ltd. · 2018-12-31 BioLineRx Ltd. (edgar:1498403) Free cash flow: -24365000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24192000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/blrx-20201231.xml#295388 Filing: 000117891321000741 Input fundies:CapitalExpenditure: 173000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/blrx-20201231.xml#310394 Filing: 000117891321000741 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	Unavailable Not reported for this period.	−USD 22.67 million Exact value Exact value: -22666000 USD 2019-01-01 – 2019-12-31: -22666000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioLineRx Ltd. · 2019-12-31 BioLineRx Ltd. (edgar:1498403) Operating Cash Flow: -22666000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22666000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/zk2227464.htm#1673621 Filing: 000117891322001134 The citation records this snapshot. The page link may show a newer release later.	USD 67,000 Exact value Exact value: 67000 USD 2019-01-01 – 2019-12-31: 67000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioLineRx Ltd. · 2019-12-31 BioLineRx Ltd. (edgar:1498403) Capital Expenditure: 67000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 67000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/zk2227464.htm#1688500 Filing: 000117891322001134 The citation records this snapshot. The page link may show a newer release later.	−USD 22.73 million Calculation and evidence -22666000 − 67000 USD Exact free cash flow: -22733000 USD 2019-01-01 – 2019-12-31: -22666000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 67000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioLineRx Ltd. · 2019-12-31 BioLineRx Ltd. (edgar:1498403) Free cash flow: -22733000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22666000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/zk2227464.htm#1673621 Filing: 000117891322001134 Input fundies:CapitalExpenditure: 67000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/zk2227464.htm#1688500 Filing: 000117891322001134 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	−USD 23.21 million Exact value Exact value: -23206000 USD 2020-01-01 – 2020-12-31: -23206000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioLineRx Ltd. · 2020-12-31 BioLineRx Ltd. (edgar:1498403) Operating Cash Flow: -23206000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23206000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891323001091/zk2329404.htm#1829038 Filing: 000117891323001091 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2020-01-01 – 2020-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioLineRx Ltd. · 2020-12-31 BioLineRx Ltd. (edgar:1498403) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891323001091/zk2329404.htm#1843908 Filing: 000117891323001091 The citation records this snapshot. The page link may show a newer release later.	−USD 23.21 million Calculation and evidence -23206000 − 0 USD Exact free cash flow: -23206000 USD 2020-01-01 – 2020-12-31: -23206000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioLineRx Ltd. · 2020-12-31 BioLineRx Ltd. (edgar:1498403) Free cash flow: -23206000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23206000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891323001091/zk2329404.htm#1829038 Filing: 000117891323001091 Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891323001091/zk2329404.htm#1843908 Filing: 000117891323001091 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	−USD 23.57 million Exact value Exact value: -23573000 USD 2021-01-01 – 2021-12-31: -23573000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioLineRx Ltd. · 2021-12-31 BioLineRx Ltd. (edgar:1498403) Operating Cash Flow: -23573000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23573000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891324001075/zk2431178.htm#1600765 Filing: 000117891324001075 The citation records this snapshot. The page link may show a newer release later.	USD 97,000 Exact value Exact value: 97000 USD 2021-01-01 – 2021-12-31: 97000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioLineRx Ltd. · 2021-12-31 BioLineRx Ltd. (edgar:1498403) Capital Expenditure: 97000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 97000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891324001075/zk2431178.htm#1614692 Filing: 000117891324001075 The citation records this snapshot. The page link may show a newer release later.	−USD 23.67 million Calculation and evidence -23573000 − 97000 USD Exact free cash flow: -23670000 USD 2021-01-01 – 2021-12-31: -23573000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 97000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioLineRx Ltd. · 2021-12-31 BioLineRx Ltd. (edgar:1498403) Free cash flow: -23670000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23573000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891324001075/zk2431178.htm#1600765 Filing: 000117891324001075 Input fundies:CapitalExpenditure: 97000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891324001075/zk2431178.htm#1614692 Filing: 000117891324001075 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	Unavailable Not reported for this period.	−USD 26.24 million Exact value Exact value: -26240000 USD 2022-01-01 – 2022-12-31: -26240000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioLineRx Ltd. · 2022-12-31 BioLineRx Ltd. (edgar:1498403) Operating Cash Flow: -26240000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26240000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm#1788922 Filing: 000117891325001123 The citation records this snapshot. The page link may show a newer release later.	USD 131,000 Exact value Exact value: 131000 USD 2022-01-01 – 2022-12-31: 131000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioLineRx Ltd. · 2022-12-31 BioLineRx Ltd. (edgar:1498403) Capital Expenditure: 131000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 131000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm#1805765 Filing: 000117891325001123 The citation records this snapshot. The page link may show a newer release later.	−USD 26.37 million Calculation and evidence -26240000 − 131000 USD Exact free cash flow: -26371000 USD 2022-01-01 – 2022-12-31: -26240000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 131000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioLineRx Ltd. · 2022-12-31 BioLineRx Ltd. (edgar:1498403) Free cash flow: -26371000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26240000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm#1788922 Filing: 000117891325001123 Input fundies:CapitalExpenditure: 131000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm#1805765 Filing: 000117891325001123 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	Unavailable Not reported for this period.	−USD 22.61 million Exact value Exact value: -22608000 USD 2023-01-01 – 2023-12-31: -22608000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioLineRx Ltd. · 2023-12-31 BioLineRx Ltd. (edgar:1498403) Operating Cash Flow: -22608000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22608000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1816036 Filing: 000117891326001581 The citation records this snapshot. The page link may show a newer release later.	USD 116,000 Exact value Exact value: 116000 USD 2023-01-01 – 2023-12-31: 116000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioLineRx Ltd. · 2023-12-31 BioLineRx Ltd. (edgar:1498403) Capital Expenditure: 116000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 116000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1829644 Filing: 000117891326001581 The citation records this snapshot. The page link may show a newer release later.	−USD 22.72 million Calculation and evidence -22608000 − 116000 USD Exact free cash flow: -22724000 USD 2023-01-01 – 2023-12-31: -22608000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 116000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioLineRx Ltd. · 2023-12-31 BioLineRx Ltd. (edgar:1498403) Free cash flow: -22724000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22608000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1816036 Filing: 000117891326001581 Input fundies:CapitalExpenditure: 116000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1829644 Filing: 000117891326001581 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	Unavailable Not reported for this period.	−USD 43.87 million Exact value Exact value: -43873000 USD 2024-01-01 – 2024-12-31: -43873000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioLineRx Ltd. · 2024-12-31 BioLineRx Ltd. (edgar:1498403) Operating Cash Flow: -43873000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43873000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1817159 Filing: 000117891326001581 The citation records this snapshot. The page link may show a newer release later.	USD 53,000 Exact value Exact value: 53000 USD 2024-01-01 – 2024-12-31: 53000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioLineRx Ltd. · 2024-12-31 BioLineRx Ltd. (edgar:1498403) Capital Expenditure: 53000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 53000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1830756 Filing: 000117891326001581 The citation records this snapshot. The page link may show a newer release later.	−USD 43.93 million Calculation and evidence -43873000 − 53000 USD Exact free cash flow: -43926000 USD 2024-01-01 – 2024-12-31: -43873000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 53000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioLineRx Ltd. · 2024-12-31 BioLineRx Ltd. (edgar:1498403) Free cash flow: -43926000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43873000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1817159 Filing: 000117891326001581 Input fundies:CapitalExpenditure: 53000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1830756 Filing: 000117891326001581 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	Unavailable Not reported for this period.	−USD 8.07 million Exact value Exact value: -8074000 USD 2025-01-01 – 2025-12-31: -8074000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioLineRx Ltd. · 2025-12-31 BioLineRx Ltd. (edgar:1498403) Operating Cash Flow: -8074000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8074000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1818282 Filing: 000117891326001581 The citation records this snapshot. The page link may show a newer release later.	USD 25,000 Exact value Exact value: 25000 USD 2025-01-01 – 2025-12-31: 25000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioLineRx Ltd. · 2025-12-31 BioLineRx Ltd. (edgar:1498403) Capital Expenditure: 25000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 25000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1831867 Filing: 000117891326001581 The citation records this snapshot. The page link may show a newer release later.	−USD 8.1 million Calculation and evidence -8074000 − 25000 USD Exact free cash flow: -8099000 USD 2025-01-01 – 2025-12-31: -8074000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 25000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioLineRx Ltd. · 2025-12-31 BioLineRx Ltd. (edgar:1498403) Free cash flow: -8099000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:24:49Z Snapshot: 7e08f5d1371aa75690b3321520b9bf371caf3aa3d7b62b4311f057c4b84beac4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1498403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8074000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1818282 Filing: 000117891326001581 Input fundies:CapitalExpenditure: 25000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm#1831867 Filing: 000117891326001581 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

434 filings · 1,116 latest values · 1,116 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001498403, 1498403, BLRX, edgar:1498403

Also known as BioLineRx Ltd, BioLineRx Ltd.

BioLineRx Ltd.

Latest quarter

Revenue

Operating margin

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation